Volume 5.47 | Nov 28

Cord Blood News 5.47 November 28, 2013
Cord Blood News
     In this issue: Publications | Reviews | Industry News | Policy News | Events | Jobs
Cell Therapy News on Facebook  Cord Blood News on Twitter
 
TOP STORY
Ligand-Independent FLT3 Activation Does Not Cooperate with MLL-AF4 to Immortalize/Transform Cord Blood CD34+ Cells
Investigators explored whether FLT3.TKD mutation or increased expression of FLT3.WT cooperates with MLL-AF4 to immortalize/transform cord blood-CD34+ hematopoietic stem/progenitor cells. [Leukemia] Abstract
Use TeSR-E7 to generate iPS cells with high quality colony morphology for easy identification and rapid subcloning. Request your sample.
 
PUBLICATIONS (Ranked by impact factor of the journal)
Platelet Gene Therapy Corrects the Hemophilic Phenotype in Immunocompromized Hemophilia A Mice Transplanted with Genetically Manipulated Human Cord Blood Stem Cells
Scientists evaluated the feasibility for lentivirus (LV)-mediated human platelet gene therapy of hemophilia A. Human platelet-FVIII (2bF8) expression was introduced by 2bF8LV-mediated transduction of human cord blood CD34+ cells followed by xeno-transplantation into immunocompromized NSG mice or NSG mice in a FVIIInull background. [Blood ] Abstract

Differences between Healthy Hematopoietic Progenitors and Leukemia Cells with Respect to CD44 Mediated Rolling versus Adherence Behavior on Hyaluronic Acid Coated Surfaces
Researchers quantitatively assessed the interaction of hematopoietic progenitor cells derived from umbilical cord blood, mobilized peripheral blood (mPB) and bone marrow (BM) from healthy donors, as well as primary leukemia blasts from PB and BM of patients with acute myeloid leukemia with hyaluronic acid. [Biomaterials] Abstract

Stage-Specific Embryonic Antigen 4 in Wharton’s Jelly-Derived Mesenchymal Stem Cells Is Not a Marker for Proliferation and Multipotency
Stage-specific embryonic antigen (SSEA)4 has been reported as a stem cell marker in bone marrow-derived MSCs, but whether SSEA4+ cells have growth and differentiation advantages over SSEA4- cells remains controversial. To gain insight into the role of SSEA4, scientists studied SSEA4+ cells in Wharton’s jelly-derived MSCs. [Tissue Eng Part A] Abstract

Human Keloid Cell Characterization and Inhibition of Growth with Human Wharton’s Jelly Stem Cell Extracts
Scientists studied the growth behavior, stemness and tumorigenic characteristics of keloid cells in prolonged culture. Since human Wharton’s jelly stem cells secrete high levels of cytokines and have anti-tumorigenic properties investigators explored its role on the inhibition of keloid growth in vitro. [J Cell Biochem] Abstract

A Nanoscaffold Impregnated with Human Wharton’s Jelly Stem Cells or Its Secretions Improves Healing of Wounds
Since nanoscaffolds provide three dimensional architectural patterns that mimic in vivo stem cell niches and aloe vera has antibacterial properties investigators evaluated the use of an aloe vera-polycaprolactone nanoscaffold impregnated with green fluorescent protein-labeled mesenchymal stem cells from the Wharton’s jelly of human umbilical cords or its conditioned medium for healing of excisional and diabetic wounds. [J Cell Biochem] Abstract

Reduced Intensity Conditioning and Co-Transplantation of Unrelated Peripheral Stem Cells Combined with Umbilical Cord Mesenchymal Stem/Stroma Cells for Young Patients with Refractory Severe Aplastic Anemia
Five young patients with a long history of severe aplastic anemia who had failed initial CSA treatment and lacked a HLA-matched sibling donor, underwent co-transplantation of unrelated donor peripheral blood stem cells and umbilical cord mesenchymal/stroma stem cells. [Int J Hematol] Abstract

Human Umbilical Cord-Derived Mesenchymal Stem Cells Downregulate Inflammatory Responses by Shifting the Treg/Th17 Profile in Experimental Colitis
Investigators evaluated the effect and mechanisms of human umbilical cord-derived mesenchymal stem cells on immune responses in murine colitis. [Pharmacology] Abstract

Learn how to complete, submit and review BMT registry forms locally. Join the Webinar.
 
REVIEWS
Mesenchymal Stromal Cells for Organ Transplantation: Different Sources and Unique Characteristics?
Recent findings on the effects of tissue and donor origin, culturing conditions and preconditioning regimens on the therapeutic effect of mesenchymal stem cells (MSC) in organ transplantation are discussed and the importance of understanding the characteristics of MSC for developing efficient therapy is stressed. [Curr Opin Organ Transplant] Abstract

Visit our reviews page to see a complete list of reviews in the cord blood research field.

Enter to Win: Free ISCT 2014 Conference Registration in Paris, France!
 
INDUSTRY NEWS
Omni Bio Announces Notice of Allowance for New Use Patent
Omni Bio Pharmaceutical, Inc. announced that it has received a Notice of Allowance from the Canadian Patent Office for the use of alpha-1 antitrypsin in reducing the risk of a non-organ transplant rejection, reducing the risk of developing graft versus host disease (GvHD) and for treating GvHD in patients who have received a cornea, bone marrow, stem cell or pancreatic islet cell transplant. [OmniBio Pharmaceutical, Inc.] Press Release

Gentium Receives EMA Orphan Drug Designation for Defibrotide for the Prevention of GvHD
Gentium SpA announced that the European Commission has granted Orphan Drug Designation to Defibrotide for the prevention of Graft versus Host Disease (GvHD). The designation follows a positive opinion released by the Committee for Orphan Medicinal Products of the European Medicines Agency (EMA). [Gentium SpA] Press Release

New wallchart from our sponsor:
Mesenchymal Stem Cells (a Nature Reviews Molecular Cell Biology collaboration). Request your free copy.
 
POLICY NEWS
National Institutes of Health (United States)

Food and Drug Administration (United States)

Center for Biologics Evaluation and Research (United States)

European Medicines Agency (European Union)

Medicines and Healthcare Products Regulatory Agency (United Kingdom)

Therapeutic Goods Administration (Australia)
 
EVENTS
NEW BMT Tandem Meetings 2014
February 26-March 2, 2014
Dallas, United States

Visit our events page to see a complete list of events in the cord blood community.
 
JOB OPPORTUNITIES
NEW Director – Clinical Immunogenetics Laboratory (Fred Hutchinson Cancer Research Center)

PhD Studentship – iNKT Cells to Prevent Graft versus Host Disease (University of Birmingham)

Postdoctoral Associate – Graft-vs.-Host Disease and Graft-vs.-Leukemia in Mouse Models (Yale University School of Medicine)

Clinical Researcher – Hematopoietic Stem Cell Transplant Program (Northwestern University- Feinberg School of Medicine)

Postdoctoral Research Fellows – Isolation of Stem Cells from Placenta and Amniotic Fluid (Wake Forest Institute for Regenerative Medicine)

Adult Stem Cell Transplant Physician (John Theurer Cancer Center)

Postdoctoral Position – Human Pluripotent and Hematopoietic Stem Cell Bioinformatics (Albert Einstein College Medicine)

Translational Clinician-Scientist – Stem Cell Transplantation (Boston Children’s Hospital)

Postdoctoral Position – Patient-Specific Stem Cell Lines: Disease Modeling, Repair and Transplantation (Columbia University)

Scientist – Particle Chemistry (STEMCELL Technologies Inc.)

Research Technologist – Human Pluripotent Stem Cell Products (STEMCELL Technologies Inc.)

Research Associate/Scientist – Antibodies Group (STEMCELL Technologies Inc.)


Recruit Top Talent: Reach more than 50,000 potential candidates by posting your organization’s career opportunities on the Connexon Creative Job Board at no cost.
 

Learn more about Cord Blood News: Archives | Events | Contact Us